Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1527.00    12.00 (0.79%)
Bid:
1532.00
Ask:
1534.00
Spread: 2.00 (0.131%)
Market Cap: £3.21b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Stabilisation Notice

31 Mar 2015 15:27

RNS Number : 0377J
Citigroup Global Markets Limited
31 March 2015
 

31st March 2015

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

Hikma Pharmaceuticals PLC

Stabilisation Notice

Citigroup Global Markets Limited. (contact: Syndicate Desk 0207 986 9000) hereby gives notice that the Stabilising Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Regulation (EC) No. 2273/2003 implementing the Market Abuse Directive (2003/6/EC).

The securities:

Issuer:

Hikma Pharmaceuticals PLC

Guarantor (if any):

Aggregate nominal amount:

$ TBC

Description:

Reg S registered

Offer price:

TBC

Other offer terms

TBC

Stabilisation:

Stabilising Manager(s):

 Citigroup Global Markets Limited

 

Stabilisation period expected to start on:

1st April 2015

Stabilisation period expected to end no later than:

1st May 2015 (30 days after the proposed issue date of the securities)

Maximum size of over-allotment facility:

5% of the aggregate nominal amount stated above.

 

In connection with the offer of the above securities, the Stabilising Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilising Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time.

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

 

This announcement and the offer of the securities to which it relates are directed only at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

 

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.

 

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STAJBMITMBTJBFA
Date   Source Headline
22nd May 20207:00 amRNSHikma receives FDA approval for generic Vascepa®
20th May 20203:42 pmRNSDirector/PDMR Shareholding
13th May 20201:28 pmRNSDirector/PDMR Shareholding
1st May 202011:30 amRNSTotal Voting Rights
30th Apr 202012:00 pmRNSResult of AGM
30th Apr 20207:00 amRNSDirectorate Change
30th Apr 20207:00 amRNSTrading Statement
16th Apr 20203:07 pmRNSDirector/PDMR Shareholding
14th Apr 20202:30 pmRNSBlock listing Interim Review
2nd Apr 20207:00 amRNSAGM Update
31st Mar 20207:00 amRNSHikma's favourable ruling in generic Vascepa®
24th Mar 202010:52 amRNSDirector/PDMR Shareholding
19th Mar 202012:00 pmRNSAnnual Financial Report
28th Feb 202012:27 pmRNSDirector/PDMR Shareholding
28th Feb 202012:26 pmRNSDirector/PDMR Shareholding
28th Feb 202012:23 pmRNSDirector/PDMR Shareholding
27th Feb 20204:40 pmRNSDirector/PDMR Shareholding
27th Feb 20204:35 pmRNSBoard Committee Changes
27th Feb 20207:05 amRNSHikma enters agreement to commercialise Ryaltris™
27th Feb 20207:00 amRNSFinal Results
4th Feb 20202:06 pmRNSTotal Voting Rights
4th Feb 20209:07 amRNSNotice of Results
15th Jan 20209:46 amRNSDirector/PDMR Shareholding
15th Jan 20209:44 amRNSDirector/PDMR Shareholding
9th Jan 20208:00 amRNSHikma announces agreement with Arecor
2nd Jan 202010:56 amRNSTotal Voting Rights
10th Dec 201912:06 pmRNSCivica Rx and Hikma announce shipment of medicines
2nd Dec 20195:12 pmRNSTotal Voting Rights
27th Nov 20197:00 amRNSHikma completes FDA response for generic Advair®
21st Nov 20192:47 pmRNSDirector/PDMR Shareholding
8th Nov 201911:17 amRNSBlock Listing Application
7th Nov 20197:00 amRNSTrading Statement
5th Nov 20199:34 amRNSTotal Voting Rights
4th Oct 20191:36 pmRNSHolding(s) in Company
1st Oct 20193:15 pmRNSBlock listing Interim Review
1st Oct 20193:02 pmRNSTotal Voting Rights
17th Sep 20199:00 amRNSHikma launches prefilled syringes in the US
10th Sep 201910:05 amRNSNotice of Accession of Guarantor
6th Sep 20193:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20195:13 pmRNSTotal Voting Rights
13th Aug 201910:20 amRNSDirector/PDMR Shareholding
9th Aug 20199:00 amRNSHikma expands nasal spray capabilities
9th Aug 20197:00 amRNSHalf-year Report
1st Aug 20193:04 pmRNSTotal Voting Rights
25th Jul 20197:00 amRNSHikma and Richter sign agreement for cariprazine
23rd Jul 20199:00 amRNSHikma and Civica Rx sign long-term agreement
8th Jul 20199:00 amRNSNotice of Results
2nd Jul 20195:54 pmRNSTotal Voting Rights
3rd Jun 20194:29 pmRNSTotal Voting Rights
17th May 20194:09 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.